Back to News
Market Impact: 0.2
SpliSense Initiates Phase 2b Trial of SPL84 in Cystic Fibrosis
Source: PR Newswire
Healthcare & Biotech
SpliSense announced a global randomized, double-blind, placebo-controlled Phase 2b trial of once-weekly inhaled SPL84 for cystic fibrosis patients receiving CFTR modulator therapy. Topline results are expected in H2 2027, creating a long-dated clinical catalyst for the company but providing no efficacy or financial data yet.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Premarket movers: Intel jumps on SK Hynix memory-chip talks, J.B. Hunt slides
- Japan has a problematic age gap: 100,000-plus residents are over 100 and the pension system is buckling
- The MLB and its Dominican pipeline is selling false promises and shady contracts to children as young as 11
- Arrowhead Pharmaceuticals at H.C. Wainwright: launch and pipeline widen
- A healthcare provider is set up for a big move higher, according to the charts
- Scientists challenge US NIH grant screening as unconstitutional